A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
Phase of Trial: Phase II/III
Latest Information Update: 18 Aug 2017
At a glance
- Drugs Upadacitinib (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors AbbVie
- 02 May 2017 Planned End Date changed from 1 Jul 2021 to 30 Jul 2021.
- 02 May 2017 Planned primary completion date changed from 1 Apr 2021 to 27 Apr 2021.
- 11 Oct 2016 Planned End Date changed from 1 Apr 2021 to 1 Jul 2021.